- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07682805
STSC-HybridAPC Trial
Snare Tip Soft Coagulation Versus Hybrid APC (ERBE) for Post-EMR Margin Thermal Ablation - A Prospective Randomized Controlled Trial
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Piecemeal endoscopic mucosal resection (EMR) of large (≥20 mm) non-pedunculated colorectal lesions was historically associated with local recurrence rates in the range of 15-20% at first surveillance when no systematic margin therapy was applied¹. The introduction of structured post-EMR margin thermal ablation has substantially altered this landscape. In a landmark randomized controlled trial, systematic thermal ablation of the resection margin reduced recurrence from 21% to 5%². Subsequent prospective and multicenter studies performed in high-volume expert centers using standardized circumferential snare-tip soft coagulation (STSC) protocols have demonstrated further reductions, with reported recurrence rates approaching 1-2%³. Most recently, Gauci et al. demonstrated that complete margin thermal ablation eliminates lesion size as a risk factor for recurrence following piecemeal EMR of large non-pedunculated colorectal polyps, reinforcing the durability and consistency of this approach in contemporary practice⁴. These findings are supported by meta-analytic data confirming that thermal margin ablation significantly reduces recurrence compared with no ablation without increasing clinically meaningful adverse events⁵. Accordingly, current international guidelines strongly recommend routine thermal ablation of the post-EMR mucosal defect margin following piecemeal resection of large colorectal lesions⁶.
Given that recurrence rates are now low when complete circumferential ablation is systematically performed, additional trials powered for recurrence would require prohibitively large sample sizes to detect incremental differences. The remaining clinically relevant gap therefore relates not to efficacy, but to procedural efficiency, reproducibility, and implementation, particularly in early-career or non-advanced interventional endoscopists.
Snare-tip soft coagulation requires precise contact-based application of thermal energy at each point sequentially along the entire resection margin, demanding consistent tip positioning and repeated fine manipulations. This technical precision may be particularly challenging for endoscopists with limited experience, increasing the risk of incomplete ablation or prolonged procedural time.
Hybrid APC (ERBE) delivers thermal energy via a non-contact argon plasma beam with a broader coagulation footprint per activation, potentially enabling faster and more reproducible circumferential coverage with fewer individual applications. The wider energy spread of Hybrid APC may therefore reduce operator-dependent variability and facilitate more consistent margin treatment, particularly in the hands of early-career endoscopists. Whether this translates into a meaningful reduction in net ablation time and improved completion rates compared with STSC has not been prospectively evaluated.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Kathleen Goodrick, BN
- Número de teléfono: +612 88905555
- Correo electrónico: kathleen.goodrick@health.nsw.gov.au
Copia de seguridad de contactos de estudio
- Nombre: Mayan Eitan, MD
- Número de teléfono: +612 88905555
- Correo electrónico: mayan.eitan@health.nsw.gov.au
Ubicaciones de estudio
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2145
- Westmead Hospital
-
Contacto:
- Kathleen Goodrick, BN
- Número de teléfono: +612 88905555
- Correo electrónico: kathleen.goodrick@health.nsw.gov.au
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age ≥18 years
- Undergoing piecemeal EMR of a non-pedunculated colorectal lesion ≥20 mm in size
- Macroscopically complete resection achieved prior to margin ablation (no visible residual adenomatous tissue at the resection base)
- Ability to provide written informed consent
Exclusion Criteria:
- Lesions requiring en bloc resection by ESD
- Lesions with suspected deep submucosal invasion based on endoscopic assessment (e.g., depressed morphology, non-lifting sign, NICE type 3 pattern, or equivalent advanced imaging criteria)
- Inflammatory bowel disease with active colitis at the lesion site
- Overt invasive carcinoma requiring surgical management
- Pregnancy
- Inability to provide informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Snare Tip Soft Coagulation (STSC)
Circumferential thermal ablation of the resection margin will be performed using the distal tip of a standard polypectomy snare in soft coagulation mode.
The tip will be applied sequentially to the entire visible mucosal defect margin to achieve complete circumferential treatment.
|
Circumferential thermal ablation of the resection margin will be performed using the distal tip of a standard polypectomy snare in soft coagulation mode.
The tip will be applied sequentially to the entire visible mucosal defect margin to achieve complete circumferential treatment.
|
|
Comparador activo: Hybrid APC (ERBE)
Circumferential thermal ablation of the resection margin will be performed using Hybrid APC (ERBE) in standard APC mode.
The argon plasma beam will be applied sequentially to the entire visible mucosal defect margin to achieve complete circumferential treatment.
Electrosurgical settings will be standardized according to unit protocol (effect and wattage predefined for Hybrid APC use).
|
Circumferential thermal ablation of the resection margin will be performed using Hybrid APC (ERBE) in standard APC mode.
The argon plasma beam will be applied sequentially to the entire visible mucosal defect margin to achieve complete circumferential treatment.
Electrosurgical settings will be standardized according to unit protocol (effect and wattage predefined for Hybrid APC use).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Net margin ablation time
Periodo de tiempo: during the procedure
|
Net margin ablation time (seconds), defined as the elapsed time from the first application of thermal energy to the resection margin (first activation in soft coagulation mode) until the operator declares completion of circumferential margin ablation.
Time will be recorded using a standardized stopwatch method by a trained assistant/nurse (or captured from time-stamped video, if available).
Interruptions unrelated to margin ablation (e.g., equipment troubleshooting) will be documented and excluded from net time where feasible, with sensitivity analyses planned.
|
during the procedure
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time (total)
Periodo de tiempo: during procedure
|
Total procedure time (minutes): from first endoscopic view of the lesion to scope withdrawal.
|
during procedure
|
|
Technical success of margin ablation
Periodo de tiempo: during procedure
|
Technical success of margin ablation: completion of circumferential thermal treatment of the entire visible mucosal defect margin as judged by the supervising endoscopist and recorded as yes/no.
|
during procedure
|
|
Instrument exchanges (count)
Periodo de tiempo: during procedure
|
Instrument exchanges (count): number of device exchanges required after completion of EMR to achieve margin ablation.
|
during procedure
|
|
Need for additional haemostatic therapy (yes/no)
Periodo de tiempo: during procedure
|
Need for additional haemostatic therapy (yes/no): including clips, APC outside assigned intervention, injectable agents, or other modalities used for bleeding control.
|
during procedure
|
|
Operator-rated ease of use (VAS 0-10)
Periodo de tiempo: during procedure
|
Operator-rated ease of use (VAS 0-10): recorded immediately post-procedure (0 = very difficult, 10 = very easy)
|
during procedure
|
|
Operator confidence (VAS 0-10)
Periodo de tiempo: during procedure
|
Operator confidence (VAS 0-10): confidence that ablation was complete (0 = not confident, 10 = fully confident).
|
during procedure
|
|
Immediate adverse events
Periodo de tiempo: during procedure
|
Immediate adverse events: intraprocedural and early post-procedural events as per standard definitions (bleeding requiring endoscopic therapy, perforation, post-polypectomy syndrome, unplanned admission).
Severity will be graded using an accepted endoscopy AE severity framework (e.g., ASGE lexicon).
|
during procedure
|
|
Cost impact (exploratory)
Periodo de tiempo: during procedure
|
Cost impact (exploratory): incremental procedural cost derived from device utilization (snare tip vs Hybrid APC), number of exchanges, and additional haemostatic devices used.
|
during procedure
|
|
Rate of incomplete STSC margin ablation by trainee operators (yes/no, Arm A only)
Periodo de tiempo: during procedure
|
Rate of incomplete STSC margin ablation by trainee operators (yes/no, Arm A only): proportion of Arm A cases in which the supervising endoscopist judged circumferential margin ablation to be incomplete at the conclusion of the trainee's attempt, necessitating supplementary ablation by the supervisor.
|
during procedure
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Michael J Bourke, MBBS, WSLHD
Publicaciones y enlaces útiles
Publicaciones Generales
- Belderbos TD, Leenders M, Moons LM, Siersema PD. Local recurrence after endoscopic mucosal resection of nonpedunculated colorectal lesions: systematic review and meta-analysis. Endoscopy. 2014 May;46(5):388-402. doi: 10.1055/s-0034-1364970. Epub 2014 Mar 26.
- Ferlitsch M, Hassan C, Bisschops R, Bhandari P, Dinis-Ribeiro M, Risio M, Paspatis GA, Moss A, Libanio D, Lorenzo-Zuniga V, Voiosu AM, Rutter MD, Pellise M, Moons LMG, Probst A, Awadie H, Amato A, Takeuchi Y, Repici A, Rahmi G, Koecklin HU, Albeniz E, Rockenbauer LM, Waldmann E, Messmann H, Triantafyllou K, Jover R, Gralnek IM, Dekker E, Bourke MJ. Colorectal polypectomy and endoscopic mucosal resection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2024. Endoscopy. 2024 Jul;56(7):516-545. doi: 10.1055/a-2304-3219. Epub 2024 Apr 26.
- Gauci JL, Mandarino FV, Kerrison C, Whitfield AM, O'Sullivan T, Gupta S, Lam B, Perananthan V, Cronin O, Lee EY, Williams SJ, Burgess N, Bourke MJ. Margin thermal ablation eliminates size as a risk factor for recurrence after piecemeal endoscopic mucosal resection of large non-pedunculated colorectal polyps. Gut. 2025 Apr 7;74(5):752-760. doi: 10.1136/gutjnl-2024-333563.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 2026/PID01713
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Adenomas de colon
-
NorgineXolomon Tree S.L.TerminadoCáncer de colon | Enfermedad del colon | Limpieza de colonEspaña, Portugal
-
Ostfold Hospital TrustTerminadoCáncer de colon | Enfermedades Benignas del ColonNoruega
-
Robert Bosch Gesellschaft für Medizinische Forschung...Ovesco Endoscopy AG; Tuebingen Scientific Medical GmbHReclutamientoAdenoma Colon | Adenoma Colon PólipoAlemania
-
PeerMedical Ltd.TerminadoCáncer de colon | Adenomas de colon | Pólipos de colon | Enfermedades del ColonIsrael
-
Intuitive SurgicalTerminadoEnfermedad benigna del colon derecho | Enfermedad maligna del colon derechoEstados Unidos
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Activo, no reclutandoCáncer de colon en estadio III AJCC v8 | Adenocarcinoma de colon | Carcinoma de colon estable microsatélite | Cáncer de colon en estadio IIB AJCC v8 | Cáncer de colon en estadio IIC AJCC v8Estados Unidos
-
University Hospitals Cleveland Medical CenterApollo Endosurgery, Inc.TerminadoTumor maligno de colon | Tumor benigno de colonEstados Unidos
-
New Day DiagnosticsActivo, no reclutandoNeoplasias Gastrointestinales | Enfermedades del Colon Funcionales | Neoplasias Intestinales | Enfermedades Rectales | Cáncer colonrectal | Adenoma | Cáncer de recto | Pólipos | Cáncer de colon | Enfermedad del colon | Pólipo de colon | Enfermedad intestinal | Lesión de Colon | Neoplasia de Colon | Adenomas Colon | Pólipo...Estados Unidos
-
University of NottinghamQuadram Institute BioscienceTerminado
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineSuspendidoCáncer de colon en estadio II | Cáncer de colon en estadio III | Cáncer de colon HER2 positivo | Cáncer de colon de tipo salvaje RASItalia